Forest Laboratories has engaged outside PR and proxy counsel as it tries to fend off a slate of board nominees backed by activist investor Carl Icahn ahead of the pharmaceutical company’s annual meeting Aug. 15.

Full Story | Subscribe to O'Dwyer's | Free E-Newsletter on PR